AU2014301629B2 - Novel antibody frameworks - Google Patents

Novel antibody frameworks Download PDF

Info

Publication number
AU2014301629B2
AU2014301629B2 AU2014301629A AU2014301629A AU2014301629B2 AU 2014301629 B2 AU2014301629 B2 AU 2014301629B2 AU 2014301629 A AU2014301629 A AU 2014301629A AU 2014301629 A AU2014301629 A AU 2014301629A AU 2014301629 B2 AU2014301629 B2 AU 2014301629B2
Authority
AU
Australia
Prior art keywords
sequence
human
framework region
nucleic acid
germ line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014301629A
Other languages
English (en)
Other versions
AU2014301629A1 (en
Inventor
Sebastian Meyer
David Urech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numab Therapeutics AG
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of AU2014301629A1 publication Critical patent/AU2014301629A1/en
Assigned to NUMAB INNOVATION AG reassignment NUMAB INNOVATION AG Alteration of Name(s) of Applicant(s) under S113 Assignors: NUMAB AG
Assigned to Numab Therapeutics AG reassignment Numab Therapeutics AG Amend patent request/document other than specification (104) Assignors: NUMAB INNOVATION AG
Application granted granted Critical
Publication of AU2014301629B2 publication Critical patent/AU2014301629B2/en
Priority to AU2020202770A priority Critical patent/AU2020202770B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2014301629A 2013-06-26 2014-06-26 Novel antibody frameworks Active AU2014301629B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020202770A AU2020202770B2 (en) 2013-06-26 2020-04-27 Novel antibody frameworks

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003264.2 2013-06-26
EP13003264 2013-06-26
PCT/EP2014/001730 WO2014206561A1 (en) 2013-06-26 2014-06-26 Novel antibody frameworks

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020202770A Division AU2020202770B2 (en) 2013-06-26 2020-04-27 Novel antibody frameworks

Publications (2)

Publication Number Publication Date
AU2014301629A1 AU2014301629A1 (en) 2015-12-10
AU2014301629B2 true AU2014301629B2 (en) 2020-02-06

Family

ID=48699516

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014301629A Active AU2014301629B2 (en) 2013-06-26 2014-06-26 Novel antibody frameworks
AU2020202770A Active AU2020202770B2 (en) 2013-06-26 2020-04-27 Novel antibody frameworks

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020202770A Active AU2020202770B2 (en) 2013-06-26 2020-04-27 Novel antibody frameworks

Country Status (12)

Country Link
US (3) US10174102B2 (enExample)
EP (1) EP3013864A1 (enExample)
JP (4) JP6708544B2 (enExample)
KR (4) KR20220029763A (enExample)
CN (2) CN113943366B (enExample)
AU (2) AU2014301629B2 (enExample)
CA (1) CA2914829A1 (enExample)
HK (1) HK1218549A1 (enExample)
IL (3) IL243311B (enExample)
NZ (1) NZ714320A (enExample)
SG (2) SG11201509899PA (enExample)
WO (1) WO2014206561A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914829A1 (en) 2013-06-26 2014-12-31 Numab Ag Novel antibody frameworks
IL293435A (en) 2015-06-15 2022-07-01 Numab Therapeutics AG Heterodimeric multispecific antibody format
BR112018067698A2 (pt) 2016-02-25 2019-01-08 Cell Medica Switzerland Ag células modificadas para imunoterapia
ES2836349T3 (es) 2016-03-17 2021-06-24 Tillotts Pharma Ag Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos
CA3011502A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnf.alpha.-antibodies and functional fragments thereof
WO2017158079A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnfalpha-antibodies and functional fragments thereof
US10774140B2 (en) 2016-03-17 2020-09-15 Numab Therapeutics AG Anti-TNFα-antibodies and functional fragments thereof
RS61412B1 (sr) 2016-03-17 2021-03-31 Tillotts Pharma Ag Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
GB201621591D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Antibody molecules and method
US12098203B2 (en) 2017-06-05 2024-09-24 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
AU2018280679B2 (en) 2017-06-05 2025-04-24 Numab Therapeutics AG Novel anti-HSA antibodies
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
KR102651965B1 (ko) 2017-06-05 2024-03-28 누맙 세러퓨틱스 아게 신규 항 cd3 항체
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
CN116199785A (zh) * 2017-06-25 2023-06-02 西雅图免疫公司 多特异性抗体及其制备和使用方法
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP3917954A1 (en) 2019-01-31 2021-12-08 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
WO2022147338A1 (en) * 2020-12-30 2022-07-07 Ascendo Biotechnology, Inc. Monoclonal antibody against human mac-1 and uses thereof
CN116848136A (zh) 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 补体c3抗原结合蛋白
CA3213283A1 (en) 2021-03-11 2022-09-15 IgGenix, Inc. Methods and systems for predicting allergic response
AR128065A1 (es) 2021-12-22 2024-03-20 Cdr Life Ag Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
CN120882418A (zh) * 2022-11-04 2025-10-31 MiNK治疗公司 B细胞成熟抗原(bcma)嵌合抗原受体不变自然杀伤t细胞及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
EP1651659A4 (en) 2003-08-07 2008-09-17 Epitomics Inc METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
CN101868477A (zh) 2007-05-21 2010-10-20 奥尔德生物制药公司 新型兔抗体人源化方法和人源化的兔抗体
MX2009013328A (es) 2007-06-25 2010-06-02 Esbatech An Alcon Biomedical R Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
JP5956752B2 (ja) * 2008-06-25 2016-07-27 エスバテック − ア ノバルティス カンパニー エルエルシー Ｖｅｇｆを阻害する安定かつ可溶性の抗体
KR101882352B1 (ko) 2008-06-25 2018-07-26 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
ES2861592T3 (es) * 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
WO2010144780A1 (en) 2009-06-12 2010-12-16 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
EP2563812A4 (en) * 2010-04-30 2016-01-13 Alexion Pharma Inc ANTIBODIES WITH REDUCED IMMUNOGENITY IN HUMANS
WO2012163519A1 (en) * 2011-05-27 2012-12-06 Dutalys Antibodies with improved folding stability
CA2914829A1 (en) 2013-06-26 2014-12-31 Numab Ag Novel antibody frameworks
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BORRAS, L. ET AL, "Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies", JOURNAL OF BIOLOGICAL CHEMISTRY, (2010), vol. 285, no. 12, pages 9054 - 9066 *

Also Published As

Publication number Publication date
CN113943366A (zh) 2022-01-18
JP2019201643A (ja) 2019-11-28
CN105579472A (zh) 2016-05-11
CN105579472B (zh) 2021-10-22
HK1218549A1 (zh) 2017-02-24
JP6708544B2 (ja) 2020-06-10
CN113943366B (zh) 2024-12-13
NZ714320A (en) 2022-02-25
US11427628B2 (en) 2022-08-30
IL243311B (en) 2022-07-01
IL293477B2 (en) 2024-11-01
SG10201811017QA (en) 2019-01-30
JP2024026176A (ja) 2024-02-28
EP3013864A1 (en) 2016-05-04
KR102286053B1 (ko) 2021-08-04
AU2014301629A1 (en) 2015-12-10
CA2914829A1 (en) 2014-12-31
US10174102B2 (en) 2019-01-08
IL243311A0 (en) 2016-03-31
WO2014206561A8 (en) 2016-02-18
US20190119359A1 (en) 2019-04-25
KR20220029763A (ko) 2022-03-08
JP2022028659A (ja) 2022-02-16
AU2020202770B2 (en) 2023-01-05
IL293477B1 (en) 2024-07-01
KR20240000622A (ko) 2024-01-02
JP2016523537A (ja) 2016-08-12
IL313351A (en) 2024-08-01
SG11201509899PA (en) 2016-01-28
AU2020202770A1 (en) 2020-05-14
US20160130326A1 (en) 2016-05-12
US20230212265A1 (en) 2023-07-06
KR20160024923A (ko) 2016-03-07
KR20210097829A (ko) 2021-08-09
IL293477A (en) 2022-08-01
WO2014206561A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
US20230212265A1 (en) Novel antibody frameworks
AU2018335823B2 (en) Novel stable antibody variable domain framework combinations
JP2016523537A5 (enExample)
US11365240B2 (en) Anti-HSA antibodies
WO2018224439A1 (en) Novel anti-hsa antibodies
HK40023336B (en) Anti-hsa antibodies
HK40023336A (en) Anti-hsa antibodies

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: NUMAB INNOVATION AG

Free format text: FORMER NAME(S): NUMAB AG

HB Alteration of name in register

Owner name: NUMAB THERAPEUTICS AG

Free format text: FORMER NAME(S): NUMAB INNOVATION AG

FGA Letters patent sealed or granted (standard patent)